Cell-derived artificial nanovesicle as a drug delivery system for malignant melanoma treatment

• Published in: Biomedicine & pharmacotherapy Vol. 147; p. 112586
• Main Authors: Lin, Ying-Yi, Chen, Chung-Yi, Ma, Dik-Lung, Leung, Chung-Hang, Chang, Chu-Yu, Wang, Hui-Min David
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-03-2022; Elsevier
• Subjects: Curcumin; Immune; Melanoma; Metastasis; Nanovesicle; Nanovesicle; Curcumin; Metastasis; Immune; Melanoma
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2021.112586

Extracellular vehicles have a natural targeting ability and immune tolerance of being usually applied in drug delivery systems; however, the purification of EVs is complicated and the production yield was quite low. We developed an artificial cellular mimetic nanovesicle (NV) with melanoma fragment membrane for the transportation with curcumin to achieve the anticancer purpose. B16F10 derived NVs were manufactured by the breakdown of cells using a series of extrusions through cut-off size filters (10 and 5 µm), and the whole procedure was easy and time-saving. To terminate the suspicion of cancer metastatic issue, B16F10 cells were treated by 30-min sonication and 1-min UVB exposure to remove genetic materials before the extrusion. B16F10 derived NV loaded with curcumin was called NV(S30U1/Cur), and the anticancer effect was evaluated by cell-based viability, immune, migration, and invasion. The results showed that NVs were manufactured by passing through 10 and 5 µm filters having an enviable production yield, and the mRNA amounts were declined within NVs produced by B16F10 cells treated with UVB in a comparison to the control group. NV(S30U1/Cur) were effectively decreased B1610 cell viability, and migratory and invasive abilities were also reduced significantly. Besides, CD8+ expression of murine primary lymphocytes was activated with CD4+ reduction by NV(S30U1/Cur) to stimulate the inherent tumor suppressive capacity in the immune system. Taken together, we established bioengineered NVs serving as novel cell mimetic nanocarriers to deliver natural compound for malignant melanoma potential immune chemotherapy.
The data used to support the findings of this study are available from the corresponding author upon requests.
[Display omitted]